A weight loss jab is now deciding what L'Oreal sells you

4%. That is how much L'Oreal's share price jumped on 22 October 2026, the day the company reported its latest sales. Investors were relieved. For months, one quiet worry had been sitting over the world's biggest beauty company: Weight loss drugs.

L'Oreal's own boss used the 22 October results call to say the drugs are already changing what the company sells. Sales still grew. But the reason investors needed reassuring tells you something bigger. A medicine built to treat diabetes and obesity is now shaping decisions inside boardrooms that have nothing to do with medicine at all.

What did L'Oreal actually say about weight loss drugs?

L'Oreal's sales for July to September rose 7.7% to EUR 11.56 billion, well above the 5.9% growth analysts had expected. On the call with investors, chief executive Nicolas Hieronimus described the rise of GLP-1 drugs such as Ozempic, Wegovy and Mounjaro as "a very important phenomenon" for the company.

He was not describing a threat he wanted to downplay. He was describing a market L'Oreal is already chasing. The company said it is now testing products on GLP-1 users in separate studies, calling that group "increasingly important" and large enough worldwide to build a strategy around.

Two of L'Oreal's own brands are already selling into it. SkinCeuticals makes a $185 serum aimed at this exact customer. Kiehl's sells a $55 plumping serum with the same group in mind. Neither product mentions diabetes or obesity drugs by name on the shelf. Both exist because of them.

Why does losing weight fast change your face?

Here is the side effect behind all of it. When someone loses a lot of weight quickly, their face can lose fat before the skin around it has time to shrink to match. The result is sagging and hollowing that looks older than the person actually is.

Read nextWhy Netflix keeps raising prices, and what every plan costs in 5 countries

New York dermatologist Paul Jarrod Frank coined the term "Ozempic face" for this in 2022. Facial fat normally cushions and stretches the skin from underneath. Strip it away fast, and skin that has also lost collagen and elastin cannot snap back into place. The face looks different, even if the number on the scale is the one the person wanted.

That single side effect is why a cosmetics company is now talking about a diabetes drug on an earnings call. It is also why "Ozempic face" turned into a product category instead of just a punchline.

Photo: Marius Vassnes / Wikimedia Commons, CC BY-SA 4.0

Which other companies have blamed weight loss drugs for their numbers?

L'Oreal is not the first big company to say this out loud, and it will not be the last. Over the past year, businesses in food, clothing and retail have each pointed to the same drug class in their own results. This is the first time anyone has put them side by side in one table.

Five different companies, five different products, one shared explanation. A grocery chain, a plus-size clothing retailer, a lingerie brand and the world's biggest snack maker do not normally end up in the same sentence. A weekly injection put them there.

How many people are actually taking these drugs?

Enough to explain why boardrooms are paying attention. A Gallup poll taken in late May and early June 2026 found that 11% of US adults currently take a GLP-1 drug for weight loss, up from just 3% in 2024. Another 15% say they have used one at some point.

3.00%2024

11.00%2026

2024	3.00%
2026	11.00%

Source: Gallup poll, 28 May-5 June 2026, published 7 July 2026

That is roughly 1 in every 10 adults in the United States alone, nearly four times as many as two years earlier. Doctors did not reach that scale by accident, and how pharmaceutical companies shape the prescription pad before a patient ever sits down is its own story.

Trending nowBootlegger data leak: The locked dashboard that was never locked

It is the same pattern as other confident health rules that turned out to be shakier than they sounded, like the idea that everyone needs exactly eight hours of sleep. A habit everyone assumed was settled science moves markets long before the science itself is settled.

What happens to the industries nobody is watching yet?

The chain reaction keeps stretching. JPMorgan analysts estimate GLP-1 drugs could wipe out between $30 billion and $55 billion a year in food and drink industry sales by 2030. Separately, analysts have put the current hit to US grocery sales from reduced snacking at about $6.5 billion.

Airlines are watching too, for a different reason. Lighter passengers mean lighter planes, and lighter planes burn less fuel. Jefferies analysts estimate the four biggest US carriers could save around $580 million a year in fuel costs combined if the drugs keep spreading at their current pace. That figure comes from an outside analyst's model, not the airlines' own books yet, but it is the kind of number that gets a finance department's attention.

Clothing retailers are feeling the shift both ways. Destination XL is losing customers who are shrinking out of plus-size ranges. Smaller stores selling fitted basics are watching the opposite problem, running short of stock in sizes that are suddenly selling faster than ever. It echoes the stock problem South African clothing retailers already have with everyday basics, just driven by a different cause.

Photo: Pittigrilli / Wikimedia Commons, CC BY-SA 4.0

So what does this actually add up to?

A drug prescribed for diabetes and obesity is now a line item on earnings calls for a French cosmetics giant, a Texas clothing chain, an American lingerie brand and the company that makes Doritos. None of these businesses voted on this. None of them had a say in how many prescriptions got written. They just had to react once the numbers started moving.

It is a reminder that some of the biggest shifts in daily life are not announced by politicians or splashed across front pages. They show up quietly first, in a 4% stock jump, a CEO's choice of words on a call most people never listen to, and a serum that costs $185 because of a side effect nobody asked for. The next earnings season will show whether this was the opening chapter or just the loudest one so far.